Lv3
245 积分 2021-03-22 加入
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
22天前
已完结
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
22天前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
22天前
已完结
Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European institute of oncology on 854 patients in 10 years
24天前
已完结
An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without HER2 Amplification (HER2-Low)
24天前
已完结
Exploring DESTINY: the Past, Present, and Future of Trastuzumab Deruxtecan
24天前
已完结
不同阶段HER2阳性乳腺癌分层治疗的要点解析
25天前
已完结
2023年CSCO指南更新解读:HER2阳性晚期乳腺癌
25天前
已完结
CDK4/6抑制剂治疗激素受体阳性人表皮生长因子受体2阴性乳腺癌临床应用专家共识(2023版)
25天前
已完结
中国早期乳腺癌卵巢功能抑制临床应用专家共识(2021年版)
1个月前
已完结
皖公网安备34019202002308
